This study demonstrated that the quininib analogue, 1–4 dihydroxy quininib (Q8), a CysLT1 antagonist showed significant anti-cancer properties in CRC based on in vitro, ex vivo and in vivo assessment of this drug. Here, CYSLTR1 is linked to cancer.